Hattie Hayes

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

The event will include presentations on artificial intelligence, ocular imaging and surgical topics

The encapsulated cell therapy from Neurotech Pharmaceuticals is the first FDA-approved treatment for MacTel

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease

This year, the European Society of Cataract and Refractive Surgeons has partnered with the Hellenic Society of Intraocular Implant and Refractive Surgery

The Visumax 800 boasts a faster laser pulse repetition rate for shorter procedures

Researchers indicated that paediatric patients with Leber congenital amaurosis experienced improvements in vision

The biosimilar to aflibercept (Eylea) has already received approval in the EU and US

Francesco Bandello, MD, FEBO, discusses the Diabetic Eye Conditions Coalition and a five-point call to action

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March

Professor Anat Loewenstein, MD, speaks about her presentation from the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting

The company shared 5-year results for lenadogene nolparvovec (Lumevoq), administered unilaterally and bilaterally to patients with Leber Hereditary Optic Neuropathy

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discusses how Gene Vision is improving patients' lives on a global scale

Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups

A qualitative study method illuminates patients’ fears for the future

Intercontinental collaboration is key to unlocking ROP in our lifetime

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

The centre will facilitate research and access to resources for the 450,000 residents of the UK who are affected by sight and hearing loss

Predictive software will use retinal imaging to identify patient risk for Alzheimer and other neurodegenerative diseases

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema

Trending topics and milestone stories from our year in ophthalmology

Our top 10 print stories highlight the core content concepts we explored this year

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

Ocular clues to a neurological conditions help clinicians understand neuromyelitis optica spectrum disorder (NMOSD)

The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)